mortality/aging
|
|
• median survival for the combined population of both males and females is 448 days, i.e., ~50 days shorter than in mice heterozygous for Trp53 tm3.1Glo alone (499 days) and in mice heterozygous for both Trp53 tm3.1Glo and Pmltm1Ppp (504 days)
(J:317504)
|
 |
• strikingly, median survival is 414 days for male mice, i.e., >100 days shorter than in males heterozygous for Trp53 tm3.1Glo alone (515 days) and in males heterozygous for both Trp53 tm3.1Glo and Pmltm1Ppp (539 days)
(J:317504)
• average survival of male mice with soft tissue sarcomas (44%) is 380 days, i.e., even shorter than in males heterozygous for both Trp53 tm3.1Glo and Pmltm1Ppp (443 days) which develop soft tissue sarcomas with a similar frequency (42%)
(J:317504)
• however, median survival for female mice is 485 days, i.e., not significantly different from that in males heterozygous for Trp53 tm3.1Glo alone (515 days)
(J:317504)
|
neoplasm
|
|
• 36% of mice develop lymphomas (when expressed as a % of tumor type); 18% of mice develop two tumor types, lymphomas and sarcomas
• 44% of mice exhibit lymphomas when tumor incidence is evaluated per mouse and expressed as a % disease/total number of mice
• when tumors are segregated by gender, 44% of males and 44% of females exhibit lymphomas (expressed as a % disease/total number of mice)
|
|
|
• ~40% of lymphoid tumors are T-cell lymphomas
|
|
|
• immunophenotyping of lymphocytes from terminally resected tumors showed that ~60% of lymphoid tumors are B-cell lymphomas
|
|
|
• 5% of mice develop carcinomas (when expressed as a % of tumor type)
(J:317504)
• 6% of mice exhibit carcinomas (when expressed as a % disease/total number of mice)
(J:317504)
|
 |
• when tumors are segregated by gender, 0% of males and 11% of females exhibit carcinomas (expressed as a % disease/total number of mice)
(J:317504)
|
|
|
• 59% of mice develop sarcomas (when expressed as a % of tumor type); 18% of mice develop two tumor types, lymphomas and sarcomas
• 72% of mice exhibit sarcomas (when expressed as a % disease/total number of mice)
• when tumors are segregated by gender, 44% of males and 11% of females exhibit soft-tissue sarcomas (expressed as a % disease/total number of mice), indicating that males lacking PML succumb to aggressive soft tissue sarcomas more frequently than females
|
|
|
• when tumors are segregated by gender, 33% of males and 56% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)
• although osteosarcomas are proportionately more abundant in female mice, survival latency is not significantly altered
|
immune system
|
|
• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 tm3.1Glo alone
|
liver/biliary system
|
|
• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 tm3.1Glo alone
|
endocrine/exocrine glands
|
|
• ~40% of lymphoid tumors are T-cell lymphomas
|
skeleton
|
|
• when tumors are segregated by gender, 33% of males and 56% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)
• although osteosarcomas are proportionately more abundant in female mice, survival latency is not significantly altered
|
hematopoietic system
|
N |
• zero of 18 mice (0%) exhibit extramedullary hematopoiesis (EMH)
• when segregated by gender, neither male nor female mice exhibit EMH
|
|
|
• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 tm3.1Glo alone
|
growth/size/body
|
N |
• average body weight is not significantly different from that in C57BL/6 wild-type controls
|
|
|
• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 tm3.1Glo alone
|
Analysis Tools